Compare TEAM & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEAM | RMD |
|---|---|---|
| Founded | 2002 | 1989 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.6B | 36.4B |
| IPO Year | 2015 | 1995 |
| Metric | TEAM | RMD |
|---|---|---|
| Price | $158.96 | $252.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 13 |
| Target Price | $251.76 | ★ $292.27 |
| AVG Volume (30 Days) | ★ 2.4M | 893.0K |
| Earning Date | 01-29-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 0.95% |
| EPS Growth | N/A | ★ 29.59 |
| EPS | N/A | ★ 9.77 |
| Revenue | ★ $5,460,076,000.00 | $5,257,400,000.00 |
| Revenue This Year | $23.41 | $9.85 |
| Revenue Next Year | $18.57 | $7.32 |
| P/E Ratio | ★ N/A | $25.82 |
| Revenue Growth | ★ 19.51 | 9.36 |
| 52 Week Low | $139.70 | $199.92 |
| 52 Week High | $326.00 | $293.81 |
| Indicator | TEAM | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 48.94 |
| Support Level | $158.26 | $250.37 |
| Resistance Level | $164.84 | $259.99 |
| Average True Range (ATR) | 4.70 | 5.54 |
| MACD | 1.30 | 0.57 |
| Stochastic Oscillator | 70.77 | 63.20 |
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.